Catalio Capital Management, LP
NEW YORK, NY
$532m in 39 US stocks at the end of 30 June 2026. The top 10 are 56.7% of the money. It changed about 44.8% of the portfolio this quarter.
Value
$532m
Stocks
39
Top 10 share
56.7%
Turnover
44.8%
What changed this quarter
New
Bought for the first time this quarter.
- Avalyn PharmaAVLN10.4% of the fund
- Johnson & JohnsonJNJ6.6% of the fund
- Parabilis MedicinesPBLS4.2% of the fund
- Protagonist TherapeuticsPTGX2.5% of the fund
- Axsome TherapeuticsAXSM2.0% of the fund
- Kailera TherapeuticsKLRA1.9% of the fund
- Odyssey TherapeuticsODTX1.6% of the fund
- Ascendis Pharma A/SASND1.6% of the fund
- KardiganKARD1.4% of the fund
- 4D Molecular TherapeuticsFDMT1.2% of the fund
- BridgeBio Oncology TherapeuticsBBOT0.5% of the fund
Added
Bought more of a stock they already held.
- Gilead SciencesGILD6.4% of the fund+64%
- BridgeBio PharmaBBIO6.4% of the fund+5%
- Syndax PharmaceuticalsSNDX5.0% of the fund+16%
- NateraNTRA4.2% of the fund+16%
- IncyteINCY4.1% of the fund+5%
- SepternaSEPN3.4% of the fund+82%
- Mineralys TherapeuticsMLYS3.3% of the fund+48%
- HeartflowHTFL3.2% of the fund+44%
- Corvus PharmaceuticalsCRVS3.0% of the fund+21%
- Structure TherapeuticsGPCR2.8% of the fund+8%
- Disc MedicineIRON2.2% of the fund+30%
- Karyopharm TherapeuticsKPTI1.7% of the fund+5%
- Eledon PharmaceuticalsELDN1.3% of the fund+3%
- Fractyl HealthGUTS0.9% of the fund+12%
- Immunocore HldgsIMCR0.9% of the fund+76%
Cut
Sold some of their stake.
- Definium TherapeuticsDFTX5.0% of the fund-46%
- Edwards LifesciencesEW2.1% of the fund-14%
- Ultragenyx PharmaceuticalRARE2.0% of the fund-63%
- VeradermicsMANE1.1% of the fund-74%
- Dyne TherapeuticsDYN1.0% of the fund-13%
- Dianthus TherapeuticsDNTH0.6% of the fund-94%
- Protara TherapeuticsTARA0.4% of the fund-10%
Sold out
Sold their entire stake.
- Ascendis Pharma A/SASND-100%
- Terns Pharmaceuticals-100%
- Soleno Therapeutics-100%
- Boston ScientificBSX-100%
- CytokineticsCYTK-100%
- Adaptive BiotechnologiesADPT-100%
- Kalvista Pharmaceuticals-100%
- uniQureQURE-100%
- Abivax SAABVX-100%
- Supernus PharmaceuticalsSUPN-100%
- Phathom PharmaceuticalsPHAT-100%
- NewAmsterdam PharmaNAMS-100%
- Tyra BiosciencesTYRA-100%
Holdings
- Avalyn PharmaAVLN
- Share
- 10.4%
- Value
- $55m
- Shares
- 1,675,830
New
- Parabilis MedicinesPBLS
- Share
- 4.2%
- Value
- $23m
- Shares
- 824,043
New
- Structure TherapeuticsGPCR
- Share
- 2.8%
- Value
- $15m
- Shares
- 276,550
+8%
- Kailera TherapeuticsKLRA
- Share
- 1.9%
- Value
- $10m
- Shares
- 468,750
New
- Odyssey TherapeuticsODTX
- Share
- 1.6%
- Value
- $9m
- Shares
- 457,839
New
- KardiganKARD
- Share
- 1.4%
- Value
- $7m
- Shares
- 312,500
New
- Immunocore HldgsIMCR
- Share
- 0.9%
- Value
- $5m
- Shares
- 148,045
+76%
- AtaiBeckleyATAI
- Share
- 0.2%
- Value
- $1m
- Shares
- 196,858
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Avalyn PharmaAVLN | 10.4% | $55m | 1,675,830 | New |
| Johnson & JohnsonJNJ | 6.6% | $35m | 138,946 | New |
| Gilead SciencesGILD | 6.4% | $34m | 269,309 | +64% |
| BridgeBio PharmaBBIO | 6.4% | $34m | 455,041 | +5% |
| Syndax PharmaceuticalsSNDX | 5.0% | $27m | 1,215,698 | +16% |
| Definium TherapeuticsDFTX | 5.0% | $26m | 562,672 | -46% |
| Bristol-Myers SquibbBMY | 4.5% | $24m | 412,961 | Held |
| Parabilis MedicinesPBLS | 4.2% | $23m | 824,043 | New |
| NateraNTRA | 4.2% | $22m | 82,181 | +16% |
| IncyteINCY | 4.1% | $22m | 191,627 | +5% |
| SepternaSEPN | 3.4% | $18m | 536,152 | +82% |
| Mineralys TherapeuticsMLYS | 3.3% | $18m | 648,722 | +48% |
| HeartflowHTFL | 3.2% | $17m | 583,055 | +44% |
| Corvus PharmaceuticalsCRVS | 3.0% | $16m | 1,080,888 | +21% |
| Structure TherapeuticsGPCR | 2.8% | $15m | 276,550 | +8% |
| Protagonist TherapeuticsPTGX | 2.5% | $13m | 106,799 | New |
| Disc MedicineIRON | 2.2% | $12m | 159,384 | +30% |
| Edwards LifesciencesEW | 2.1% | $11m | 124,778 | -14% |
| Axsome TherapeuticsAXSM | 2.0% | $11m | 43,182 | New |
| Ultragenyx PharmaceuticalRARE | 2.0% | $11m | 316,252 | -63% |
| Kailera TherapeuticsKLRA | 1.9% | $10m | 468,750 | New |
| Karyopharm TherapeuticsKPTI | 1.7% | $9m | 940,855 | +5% |
| Odyssey TherapeuticsODTX | 1.6% | $9m | 457,839 | New |
| Ascendis Pharma A/SASND | 1.6% | $8m | 31,759 | New |
| KardiganKARD | 1.4% | $7m | 312,500 | New |
| Eledon PharmaceuticalsELDN | 1.3% | $7m | 1,695,071 | +3% |
| 4D Molecular TherapeuticsFDMT | 1.2% | $6m | 471,254 | New |
| VeradermicsMANE | 1.1% | $6m | 45,856 | -74% |
| Dyne TherapeuticsDYN | 1.0% | $5m | 244,929 | -13% |
| Fractyl HealthGUTS | 0.9% | $5m | 6,168,749 | +12% |
| Immunocore HldgsIMCR | 0.9% | $5m | 148,045 | +76% |
| Dianthus TherapeuticsDNTH | 0.6% | $3m | 32,941 | -94% |
| BridgeBio Oncology TherapeuticsBBOT | 0.5% | $2m | 318,407 | New |
| Protara TherapeuticsTARA | 0.4% | $2m | 520,148 | -10% |
| HyperfineHYPR | 0.3% | $2m | 1,320,041 | Held |
| AtaiBeckleyATAI | 0.2% | $1m | 196,858 | Held |
| Metagenomi TherapeuticsMGX | 0.1% | $629,502 | 528,993 | Held |
| Outset MedicalOM | <0.1% | $510,965 | 118,279 | Held |
| Faeth TherapeuticsFTH | <0.1% | $367,950 | 14,718 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 11.6% since 30 June 2025.
Where the money is
Health care96.3%
Other3.7%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.